oncnursingnews6h
How to Overcome 4 Common Barriers to Cancer Clinical Trial Access
An oncology nurse discusses 4 common barriers certain patient populations face when it comes to oncology clinical trials, and ...
oncnursingnews1d
FDA Delays Decision Date for Zenocutuzumab in Lung, Pancreatic Cancer
The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of ...
oncnursingnews2d
John Sweetenham, MD, FACP, FRCP
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews2d
ERIC BLACKSTONE, MA
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews2d
Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer
The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.
oncnursingnews3d
Julie Huynh, MS
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews3d
Letter Warns Clinicians of Severe Infections With Pralsetinib for NSCLC
An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...
oncnursingnews4d
Barbara A. Leone, RN, BSN, CCM
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews4d
Kathryn Canavan
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews4d
Cilta-Cel May Outperform Standard Care for Relapsed, Refractory Myeloma
An indirect comparison found that cilta-cel may be better than standard of care for patients with lenalidomise-refractory relapsed/refractory myeloma. Ciltacabtagene autoleucel (cilta-cel; Carvykti) ...
oncnursingnews5d
Jennifer L. Redmond, DrPH
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...